Café

© 2026 Longbridge｜Terms of Service Privacy Policy

BDTX

BDTX

2.0600.49%( +0.010 )

LongbridgeAI

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News

StockTitan

May 21, 2026 at 08:15 AM

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News

Login to unlock158characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Black Diamond Therapeutics

USBDTX

+0.49%

Direxion S&P Biotech Bull 3X

USLABU

Ark Genomic Revolution ETF

USARKG